Vic Myer

Vic Myer is President and Chief Scientific Officer at Chroma Medicine and an Advisor at Atlas Venture. He also serves as an Independent Board member at KromaTid, Inc, an advisor to the NIH SCGE, and a SAB member at both Obsidian Therapeutics and Life Edit Therapeutics. Previously, he was Chief Technology Officer of Editas Medicine where he led the genome editing platform, CMC and chemistry departments. He has more than 20 years of experience in the biotech industry. At the Novartis Institutes for Biomedical Research, he led a large, technology-focused target discovery, target validation, and lead-finding group in the Developmental and Molecular Pathways department for 11 years. Prior to Novartis, Dr. Myer focused on industrializing and using ‘omics technologies at Millennium, Akceli, and Corning. He has B.S. from Cornell, a Ph.D. from Yale, and did his post-doc at MIT/The Whitehead.